pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·1h ago·1 min read
save

CVS to split into two companies in stunning strategic about-face

Nov 4, 2026·read at BioPharma Dive ↗

The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is always better in the healthcare industry.

source

Reporting by BioPharma Dive.

read at BioPharma Dive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 47m agoNovo gets much-needed lift as Wegovy pill tops Wall Street forecastsBioPharma Dive
  • 1h agoBiopharma likely to climb higher after ‘blue wave,’ analysts sayBioPharma Dive
  • 23h agoVertex, ahead of FDA decision, calms fears surrounding kidney drugBioPharma Dive
  • 1d agoMedicare Part D premiums are spiking 50% on average next year, KFF findsBioPharma Dive
  • 1d agoUniQure gets an FDA decision date; Teva scraps brain drug studyBioPharma Dive